Deutsche Bank
BTAI icon

Deutsche Bank’s BioXcel Therapeutics BTAI Stock Holding History

Deutsche Bank’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,096
Closed -$49.5K – 3574
2024
Q1 		$49.5K Hold
1,096
– – ﹤0.01% 3399
2023
Q4 		$51.7K Buy
1,096
+942
+612% +$52.4K ﹤0.01% 3420
2023
Q3 		$6.23K Sell
154
-693
-82% -$70K ﹤0.01% 3591
2023
Q2 		$90.2K Sell
847
-882
-51% -$294K ﹤0.01% 3314
2023
Q1 		$516K Buy
1,729
+218
+14% +$93.1K ﹤0.01% 2469
2022
Q4 		$519K Sell
1,511
-68
-4% -$16.4K ﹤0.01% 2430
2022
Q3 		$298K Sell
1,579
-101
-6% -$23.4K ﹤0.01% 2694
2022
Q2 		$354K Buy
1,680
+141
+9% +$29.7K ﹤0.01% 2801
2022
Q1 		$514K Sell
1,539
-250
-14% -$72.5K ﹤0.01% 2728
2021
Q4 		$582K Sell
1,789
-267
-13% -$115K ﹤0.01% 2739
2021
Q3 		$999K Buy
2,056
+542
+36% +$238K ﹤0.01% 2610
2021
Q2 		$704K Buy
1,514
+24
+2% +$13.1K ﹤0.01% 3007
2021
Q1 		$1.03M Sell
1,490
-56
-4% -$45K ﹤0.01% 2639
2020
Q4 		$1.14M Buy
1,546
+264
+21% +$206K ﹤0.01% 2351
2020
Q3 		$890K Buy
1,282
+78
+6% +$58.6K ﹤0.01% 2274
2020
Q2 		$1.02M Buy
1,204
+228
+23% +$149K ﹤0.01% 2212
2020
Q1 		$349K Sell
976
-2
-0.2% -$719 ﹤0.01% 2665
2019
Q4 		$227K Buy
978
+872
+823% +$87.7K ﹤0.01% 3145
2019
Q3 		$10K Sell
106
-178
-63% -$28.1K ﹤0.01% 4495
2019
Q2 		$49K Buy
+284
New +$48.1K ﹤0.01% 4513
2019
Q1 		– Sell
-322
Closed -$19K – 5189
2018
Q4 		$19K Buy
322
+128
+66% +$10.8K ﹤0.01% 4746
2018
Q3 		$24K Buy
+194
New +$28.8K ﹤0.01% 4901

Other funds holding BTAI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Deutsche Bank's BTAI Position: Q2 2024 in Review

Deutsche Bank sold out of BioXcel Therapeutics (BTAI) in Q2 2024, closing a stake of 1,096 shares — an estimated $49.5K sold.

Deutsche Bank first reported a position in BTAI in Q3 2018 and held it in 22 quarters. The position peaked at $1.14M in Q4 2020. 74 funds tracked by Wall St. Rank hold BTAI as of Q2 2024.

  • Deutsche Bank reported no remaining BioXcel Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Deutsche Bank sold 1,096 BioXcel Therapeutics shares in Q2 2024, an estimated $49.5K.
  • Deutsche Bank first reported a position in BioXcel Therapeutics in Q3 2018 and held it in 22 quarters.
  • Deutsche Bank's BioXcel Therapeutics position peaked at $1.14M in Q4 2020.
  • 74 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2024.

Based on Deutsche Bank's 13F filing for Q2 2024, filed 14 Aug 2024.